Clinical usefulness of cancer markers in primary breast cancer [PDF]
, 2011 The aim of this study was to investigate the diagnostic power of CA 549, MSA and CA 15-3 in identifying breast cancer. The study included 232 patients of which 56 were healthy, 43 had benign breast cancer and 191 with other growths.
Verring, A. +3 more
core +1 more source
Metastatic niche shaped by host factors influences disseminated cancer cell fate
FEBS Letters, EarlyView.Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward +2 more
wiley +1 more source
The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers
Molecular Oncology, EarlyView.The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce +11 more
wiley +1 more source
Occult Breast Carcinoma Presenting as Scalp Metastasis
Case Reports in Oncology, 2017 Breast cancer is the most common tumor among women, and approximately 6% of the patients have de novo metastatic breast cancer. Occult breast cancer accounts for only 0.1–0.8% of the cases and most commonly presents with axillary lymphadenopathy.
Ricardo L.B. Costa +3 more
doaj +1 more source
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. [PDF]
PLoS ONE, 2011 Tumor tolerance and immune suppression remain formidable obstacles to the efficacy of immunotherapies that harness the immune system to eradicate breast cancer.
Laura M Hix +5 more
doaj +1 more source
Breast surgery for metastatic breast cancer
Cochrane Database of Systematic ReviewsMetastatic breast cancer is not curable, but women with this condition are living longer. While breast surgery is not typically part of the treatment for metastatic disease, retrospective studies suggest it might improve survival. These studies have limitations, including selection bias.
Giuliano Tosello +9 more
openaire +2 more sources
Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer
Molecular Oncology, EarlyView.Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley +1 more source
Changing the Landscape for People Living with Metastatic Breast Cancer: Metastatic Breast Cancer Landscape Analysis - Research Report October 2014 [PDF]
, 2014 40,000 women and men in America every year and 20-30% of those diagnosed with early stage breast cancer will go on to develop recurrent, metastatic disease.
core +2 more sources
Melatonin Does Not Alter Cell Proliferation in Metastatic Breast Cancer Cells
Proceedings, 2018 Breast cancer treatments continue to be investigated with supported by new treatment methods. Melatonin is a hormone that can be effective in the treatment of breast cancer due to its anti-oxidant effect.
Gamze Tanriover +2 more
doaj +1 more source